Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 1;7(1):107-14.
doi: 10.7150/jca.13503. eCollection 2016.

HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions

Luciano Mariani  1 , Maria Teresa Sandri  2 , Mario Preti  3 , Massimo Origoni  4 , Silvano Costa  5 , Paolo Cristoforoni  6 , Fabio Bottari  2 , Mario Sideri  1
Affiliations
Review

HPV-Testing in Follow-up of Patients Treated for CIN2+ Lesions

Luciano Mariani et al. J Cancer. .

Abstract

Persistent positivity of HPV-DNA testing is considered a prognostic index of recurrent disease in patients treated for CIN2+. HPV detection, and particularly genotyping, has an adequate high rate of sensitivity and specificity (along with an optimal reproducibility), for accurately predicting treatment failure, allowing for an intensified monitoring activity. Conversely, women with a negative HPV-test 6 months after therapy have a very low risk for residual/recurrent disease, which leads to a more individualized follow-up schedule, allowing for a gradual return to the normal screening scheme. HPV testing should be routinely included (with or without cytology) in post-treatment follow-up of CIN2+ patients for early detection of recurrence and cancer progression. HPV genotyping methods, as a biological indicator of persistent disease, could be more suitable for a predictive role and risk stratification (particularly in the case of HPV 16/18 persistence) than pooled HPV-based testing. However, it is necessary to be aware of the performance of the system, adhering to strict standardization of the process and quality assurance criteria.

Keywords: CIN recurrence; CIN2+; HPV-testing; follow-up; genotyping.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, Makrydimas G, Tofoski J, Roukos DH. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev. 2001;30:205–11. - PubMed
    1. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Clinical applications of HPV testing: A summary of meta-analyses. Vaccine. 2006;24:78–89. - PubMed
    1. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH, de Schipper FA, Snijders PJ, Voorhorst FJ, van Kemenade FJ, Rozendaal L, Meijer CJ. HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. ObstetGynecol Surv. 2004;59:543–53. - PubMed
    1. Kocken M, Uijterwaal MH, de Vries AL, Berkhof J, Ket JC, Helmerhorst TJ, Meijer CJ. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011;12:441–50. - PubMed
    1. Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, Kitchener HC. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet. 1997;349:978–80. - PubMed

LinkOut - more resources